Erratum to: A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers (European Journal of Clinical Pharmacology (2013) 69, (1997-1999) DOI: 10.1007/s00228-013-1561-1);A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers

European Journal of Clinical Pharmacology

Volumn 69, Issue 12, 2013, Pages 1997-1999

  Pedersen, Rasmus Steen ^a   Damkier, Per ^a,b   Christensen, Mette Marie Hougaard ^a   Brosen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adverse reactions; Cocktail; Cytochrome P450; Phenotyping

Indexed keywords

CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; LOSARTAN; LOSARTAN POTASSIUM; OMEPRAZOLE; TRAMADOL;

ADULT; ADVERSE DRUG REACTION; ARTICLE; CATALYSIS; DIZZINESS; DYSURIA; ENZYME ACTIVITY; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; MIDDLE AGED; NAIL DISEASE; NAUSEA; NORMAL HUMAN; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; SWEATING; UNSPECIFIED SIDE EFFECT; VOMITING; YOUNG ADULT;

ADULT; CAFFEINE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG COMBINATIONS; FEMALE; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; LOSARTAN; MALE; MIDDLE AGED; OMEPRAZOLE; PHENOTYPE; TRAMADOL; YOUNG ADULT;

EID: 84892373719     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1663-4     Document Type: Erratum

References (25)

1. Fuhr U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther 81(2):270-283. doi:10.1038/sj.clpt.6100050
2. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5(6):358-363
3. Babaoglu MO, Yasar U, Sandberg M, Eliasson E, Dahl ML, Kayaalp SO, Bozkurt A (2004) CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 60(5):337-342. doi:10.1007/S00228-004-0785-5
4. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic S, Grant D, Meyer UA, Staib AH (1996) Evaluation of caffeine as a test drug for CYPIA2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6(2):159-176. doi:10.1097/00008571-199604000- 00003
5. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar U, Bertilsson L (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73(6):517-528. doi:10.1016/S0009-9236(03)00050-X
6. Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, Shin JG (2007) Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome p450 Isoforms in vivo. Clin Pharmacol Ther 82(5):531-540. doi:10.1038/Sj.Clpt.6100187
7. Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Nielsen F, Brosen K (2009) Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol 65(9):887-894. doi:10.1007/s00228-009-0657-0
8. Rasmussen BB, Brix TH, Kyvik KO, Brosen K (2002) The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 12(6):473-478. doi:10.1097/00008571-200208000-00008
9. Rasmussen BB, Brosen K (1996) Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 18(3):254-262. doi:10.1097/00007691-199606000-00006
10. Rasmussen BB, Brosen K (1997) Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans. Brit J Clin Pharmacol 43(3):253-258. doi:10.1111/J.1365-2125.1997.00546.X
11. Damkier P, Brosen K (2000) Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probebased assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clin Pharmacol Ther 68(2):199-209. doi:10.1067/Mcp.2000.108532
12. Pedersen RS, Damkier P, Brosen K (2005) Tramadol as a new probe for cytochrome P450 2D6 phenotyping: A population study. Clin Pharmacol Ther 77(6):458-467. doi:10.1016/J.Clpt.2005.01.014
13. Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, Brosen K, Sindrup SH (2009) The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol 104(4):335-344. doi:10.1111/J.1742-7843.2009.00378.X
14. Pedersen RS, Brosen K, Nielsen F (2003) Enantioselective HPLC method for quantitative determination of tramadol and Odesmethyltramadol in plasma and urine: Application to clinical studies. Chromatographia 57(5-6):279-285. doi:10.1007/Bf02492397
15. Nielsen AG, Damkier P, Pedersen RS, Brosen K (2009) Paroxetine is a dose dependent inhibitor of tramadol's O-demethylation via Cyp2d6: pharmacokinetic and-dynamic consequences. Basic Clin Pharmacol 105:66-66
16. The Danish Ministry of Health and Prevention (2012) Notice on reporting of adverse reactions. BEK number 826 (01/08/2012) Available from: http://www.retsinfo.dk
17. Grünenthal. Tramadol hydrochloride, Summary of Product Characteristics. Grünenthal, Aachen, Germany. Last updated on the eMC: 18 Dec 2012
18. Merck Sharp & Dohme. Cozaar, Summary of Product Characteristics. Merck Sharp & Dohme, Whitehouse Station, NJ. Last updated on the eMC: 13 January 2012
19. Astra Zeneca. Losec, Summary of Product Characteristics. Astra Zeneca, London, UK. Last updated on the eMC: 21 December 2012
20. Aronson JJ (2006) Meyler's side effects of drugs. The International encyclopedia of adverse drug reactions and interactions. Elsevier, Amsterdam
21. Wu WN, McKown LA, Liao S (2002) Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica; the fate of foreign compounds in biological systems 32(5):411-425. doi:10.1080/00498250110113230
22. Grond S, Sablotzki A (2004) Clinical pharmacology of tramadol. Clin Pharmacokinet 43(13):879-923
23. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL (1992) Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 260(1):275-285
24. Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, Hertrampf T, Kogel B, Schiene K, Strassburger W, Terlinden R, Tzschentke TM (2012) Mechanistic and functional differentiation of tapentadol and tramadol. Expert Oin Pharmacother 13(10):1437-1449. doi:10.1517/14656566.2012.696097
25. Stoops WW, Lofwall MR, Nuzzo PA, Craig LB, Siegel AJ, Walsh SL (2012) Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment. Psychopharmacology (Berl) 223(4):427-438. doi:10.1007/s00213-012- 2739-4